Journal
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 77, Issue 6, Pages 193-197Publisher
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2007.77.193
Keywords
-
Ask authors/readers for more resources
Parasite resistance to conventional antimalarial medicines has led, in recent years, to a dramatic shift in malaria treatment. Sixty-seven countries with endemic Plasmodium falciparum malaria, 41 of them in Africa, have recently adopted the highly effective artemisinin-based combination therapies (ACTS). In 2005, 31.3 million ACT treatment courses were procured globally for public sector use, 25.5 million of them in Africa. However, in the 39 countries, and in particular the 21 African countries in which ACTS are being deployed, access to these medicines is still unacceptably low. After a period of market instability, the global manufacturing capacity for ACTS is now sufficient to meet the demand. However, increased and sustained financing will be necessary to extend the current levels of ACT coverage. Artemisinins as monotherapies are widely available in the private sector of 47 endemic countries, and their consumption will, if unabated, promote resistance to artemisinins and compromise the effectiveness of ACTs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available